Vericel Corporation (VCEL)
After hours:
| Previous close | 43.35 |
| Open | 42.76 |
| Bid | 42.18 x 100 |
| Ask | 42.39 x 100 |
| Day's range | 41.51 - 43.18 |
| 52-week range | 30.18 - 53.05 |
| Volume | |
| Avg. volume | 388,398 |
| Market cap | 2.055B |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | 4,229.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://in
- GlobeNewswire
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at
- GlobeNewswire
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for
